FDA Approves First mRNA Flu Vaccine M-Fluvisa for Adults 50 and Older
The U.S. Food and Drug Administration (FDA) approved the first messenger RNA flu vaccine, M-Fluvisa, granting adults aged 50 and older a new option to protect against influenza and its complications, alkhaleej.ae reported.
In a Phase 3 clinical trial involving more than 40,000 participants aged 50 and older, roughly 2% of those who received the mRNA vaccine contracted the flu, compared to about 2.8% of participants who received a standard-dose traditional influenza vaccine. As reported by alkhaleej.ae, this equates to a 27% reduction in the relative risk of influenza infection for the group receiving M-Fluvisa compared to the conventional vaccine.
Eligibility and Recommendations for the 2026-2027 Season
M-Fluvisa is authorized for adults aged 50 and older. Centers for Disease Control and Prevention (CDC) does not express a preference for any specific licensed flu vaccine. For adults aged 65 and older, several enhanced influenza vaccines are available, and M-Fluvisa now serves as an additional choice.
The formulation for the 2026-2027 season does not contain egg protein, antibiotics, or preservatives. Clinical trials showed that temporary side effects—such as injection site pain, fatigue, headache, muscle or joint pain, chills, and underarm swelling or pain—lasted an average of about two days.
WHO Recommends Vaccination Before Flu Season Begins
As winter approaches, concerns over rising flu rates grow, prompting questions regarding the proper timing of the immunization as virus circulation periods vary by region rather than tying strictly to the winter calendar. The World Health Organization recommends receiving the shot just before the virus season begins, though immunization remains beneficial even after the season starts.
Vaccination is particularly vital for high-risk populations, including older adults, young children, pregnant individuals, people with chronic medical conditions or weakened immune systems, and long-term care residents, according to alkhaleej.ae. Healthcare personnel and those caring for vulnerable individuals also benefit from early immunization to prevent severe illness and hospitalizations.
M-Fluvisa Does Not Alter DNA or Cause Influenza
Does the M-Fluvisa mRNA flu vaccine change human DNA?
No, the mRNA inside the vaccine does not enter the cell nucleus or alter genetic material. Once cells finish using the temporary instructions to build the target protein, the mRNA naturally breaks down inside the body. The vaccine does not contain a whole influenza virus, meaning it cannot cause influenza.
What are the most common side effects of M-Fluvisa?
Participants frequently reported mild-to-moderate injection site tenderness, fatigue, headaches, muscle or joint aches, chills, and underarm swelling that typically resolved within roughly two days.
Is October the only month suitable for receiving a flu shot?
While health agencies recommend completing vaccination during October before peak transmission occurs, receiving the vaccine later in the season still offers protection as long as the influenza virus remains active in the community.
Related reading